JPMorgan Chase & Co. grew its holdings in shares of Cambrex Co. (NYSE:CBM) by 38.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 212,066 shares of the biotechnology company’s stock after purchasing an additional 58,931 shares during the period. JPMorgan Chase & Co. owned 0.64% of Cambrex worth $11,091,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of CBM. Natixis Advisors L.P. increased its holdings in shares of Cambrex by 6.7% in the 1st quarter. Natixis Advisors L.P. now owns 26,733 shares of the biotechnology company’s stock worth $1,398,000 after acquiring an additional 1,677 shares during the period. Scout Investments Inc. increased its holdings in shares of Cambrex by 8.3% in the 1st quarter. Scout Investments Inc. now owns 91,050 shares of the biotechnology company’s stock worth $4,762,000 after acquiring an additional 6,950 shares during the period. Canandaigua National Bank & Trust Co. acquired a new stake in shares of Cambrex in the 1st quarter worth about $322,000. BlackRock Inc. increased its holdings in shares of Cambrex by 2.2% in the 1st quarter. BlackRock Inc. now owns 4,253,444 shares of the biotechnology company’s stock worth $222,455,000 after acquiring an additional 90,694 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Cambrex by 0.4% in the 1st quarter. Northern Trust Corp now owns 580,936 shares of the biotechnology company’s stock worth $30,383,000 after acquiring an additional 2,336 shares during the period.
A number of analysts recently weighed in on CBM shares. Zacks Investment Research cut shares of Cambrex from a “hold” rating to a “sell” rating in a report on Tuesday, March 20th. ValuEngine cut shares of Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Cambrex has an average rating of “Hold” and an average target price of $60.00.
CBM stock opened at $47.30 on Friday. Cambrex Co. has a fifty-two week low of $42.55 and a fifty-two week high of $62.30. The stock has a market capitalization of $1.56 billion, a P/E ratio of 14.30, a PEG ratio of 1.15 and a beta of 2.27.
Cambrex (NYSE:CBM) last released its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported $0.72 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.22. Cambrex had a net margin of 18.69% and a return on equity of 21.00%. The business had revenue of $141.10 million for the quarter, compared to analysts’ expectations of $104.44 million. During the same quarter last year, the company earned $0.68 EPS. The company’s revenue for the quarter was up 34.4% compared to the same quarter last year. analysts expect that Cambrex Co. will post 2.73 earnings per share for the current year.
In related news, COO Shawn Cavanagh sold 40,000 shares of the stock in a transaction dated Tuesday, May 8th. The shares were sold at an average price of $49.69, for a total value of $1,987,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven M. Klosk sold 55,000 shares of the stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $45.64, for a total transaction of $2,510,200.00. Following the completion of the transaction, the chief executive officer now owns 218,328 shares of the company’s stock, valued at approximately $9,964,489.92. The disclosure for this sale can be found here. Insiders sold a total of 162,500 shares of company stock valued at $7,837,700 in the last quarter. 2.42% of the stock is currently owned by insiders.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.